Middle-East and Africa Hypertension Drugs Market

ID: MRFR/Pharma/1967-HCR
55 Pages
Satyendra Maurya
Last Updated: April 06, 2026
Middle-East and Africa Hypertension Drugs Market information, by Type (Thiazide diuretics, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Calcium channel blockers, Renin inhibitors, Alpha blockers, Alpha-beta blockers, Central-acting agents, Vasodilators, Aldosterone antagonists) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type (USD Million)
      1. 4.1.1 Thiazide diuretics
      2. 4.1.2 Beta blockers
      3. 4.1.3 Angiotensin-converting enzyme (ACE) inhibitors
      4. 4.1.4 Angiotensin II receptor blockers
      5. 4.1.5 Calcium channel blockers
      6. 4.1.6 Renin inhibitors
      7. 4.1.7 Alpha blockers
      8. 4.1.8 Alpha-beta blockers
      9. 4.1.9 Central-acting agents
      10. 4.1.10 Vasodilators
      11. 4.1.11 Aldosterone antagonists
      12. 4.1.12 others
    2. 4.2 Healthcare, BY Region (USD Million)
      1. 4.2.1 North America
        1. 4.2.1.1 US
        2. 4.2.1.2 Canada
      2. 4.2.2 Europe
        1. 4.2.2.1 Germany
        2. 4.2.2.2 UK
        3. 4.2.2.3 France
        4. 4.2.2.4 Russia
        5. 4.2.2.5 Italy
        6. 4.2.2.6 Spain
        7. 4.2.2.7 Rest of Europe
      3. 4.2.3 APAC
        1. 4.2.3.1 China
        2. 4.2.3.2 India
        3. 4.2.3.3 Japan
        4. 4.2.3.4 South Korea
        5. 4.2.3.5 Malaysia
        6. 4.2.3.6 Thailand
        7. 4.2.3.7 Indonesia
        8. 4.2.3.8 Rest of APAC
      4. 4.2.4 South America
        1. 4.2.4.1 Brazil
        2. 4.2.4.2 Mexico
        3. 4.2.4.3 Argentina
        4. 4.2.4.4 Rest of South America
      5. 4.2.5 MEA
        1. 4.2.5.1 GCC Countries
        2. 4.2.5.2 South Africa
        3. 4.2.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Boehringer Ingelheim (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bristol-Myers Squibb (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 GSK (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Lupin Pharmaceuticals (IN)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
      10. 5.2.10 Mylan (US)
        1. 5.2.10.1 Financial Overview
        2. 5.2.10.2 Products Offered
        3. 5.2.10.3 Key Developments
        4. 5.2.10.4 SWOT Analysis
        5. 5.2.10.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TYPE
    4. 6.4 CANADA MARKET ANALYSIS BY TYPE
    5. 6.5 EUROPE MARKET ANALYSIS
    6. 6.6 GERMANY MARKET ANALYSIS BY TYPE
    7. 6.7 UK MARKET ANALYSIS BY TYPE
    8. 6.8 FRANCE MARKET ANALYSIS BY TYPE
    9. 6.9 RUSSIA MARKET ANALYSIS BY TYPE
    10. 6.10 ITALY MARKET ANALYSIS BY TYPE
    11. 6.11 SPAIN MARKET ANALYSIS BY TYPE
    12. 6.12 REST OF EUROPE MARKET ANALYSIS BY TYPE
    13. 6.13 APAC MARKET ANALYSIS
    14. 6.14 CHINA MARKET ANALYSIS BY TYPE
    15. 6.15 INDIA MARKET ANALYSIS BY TYPE
    16. 6.16 JAPAN MARKET ANALYSIS BY TYPE
    17. 6.17 SOUTH KOREA MARKET ANALYSIS BY TYPE
    18. 6.18 MALAYSIA MARKET ANALYSIS BY TYPE
    19. 6.19 THAILAND MARKET ANALYSIS BY TYPE
    20. 6.20 INDONESIA MARKET ANALYSIS BY TYPE
    21. 6.21 REST OF APAC MARKET ANALYSIS BY TYPE
    22. 6.22 SOUTH AMERICA MARKET ANALYSIS
    23. 6.23 BRAZIL MARKET ANALYSIS BY TYPE
    24. 6.24 MEXICO MARKET ANALYSIS BY TYPE
    25. 6.25 ARGENTINA MARKET ANALYSIS BY TYPE
    26. 6.26 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    27. 6.27 MEA MARKET ANALYSIS
    28. 6.28 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    29. 6.29 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    30. 6.30 REST OF MEA MARKET ANALYSIS BY TYPE
    31. 6.31 KEY BUYING CRITERIA OF HEALTHCARE
    32. 6.32 RESEARCH PROCESS OF MRFR
    33. 6.33 DRO ANALYSIS OF HEALTHCARE
    34. 6.34 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    35. 6.35 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    36. 6.36 SUPPLY / VALUE CHAIN: HEALTHCARE
    37. 6.37 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    38. 6.38 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
    39. 6.39 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TYPE, 2025-2035 (USD Million)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TYPE, 2025-2035 (USD Million)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TYPE, 2025-2035 (USD Million)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TYPE, 2025-2035 (USD Million)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TYPE, 2025-2035 (USD Million)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TYPE, 2025-2035 (USD Million)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TYPE, 2025-2035 (USD Million)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TYPE, 2025-2035 (USD Million)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TYPE, 2025-2035 (USD Million)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TYPE, 2025-2035 (USD Million)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TYPE, 2025-2035 (USD Million)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TYPE, 2025-2035 (USD Million)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TYPE, 2025-2035 (USD Million)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TYPE, 2025-2035 (USD Million)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TYPE, 2025-2035 (USD Million)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TYPE, 2025-2035 (USD Million)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TYPE, 2025-2035 (USD Million)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TYPE, 2025-2035 (USD Million)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TYPE, 2025-2035 (USD Million)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TYPE, 2025-2035 (USD Million)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TYPE, 2025-2035 (USD Million)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TYPE, 2025-2035 (USD Million)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TYPE, 2025-2035 (USD Million)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TYPE, 2025-2035 (USD Million)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TYPE, 2025-2035 (USD Million)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TYPE, 2025-2035 (USD Million)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TYPE, 2025-2035 (USD Million)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TYPE, 2025-2035 (USD Million)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Million, 2025-2035)

  • Thiazide diuretics
  • Beta blockers
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin II receptor blockers
  • Calcium channel blockers
  • Renin inhibitors
  • Alpha blockers
  • Alpha-beta blockers
  • Central-acting agents
  • Vasodilators
  • Aldosterone antagonists
  • others